Germantown-based Cambridge Major Laboratories announced that it will dedicate its new, 125,000-square-foot active pharmaceutical ingredient facility in Germantown on Thursday, July 30.
The facility will provide a supply option for the pharmaceutical and biotechnology industries, and is in response to the company’s need for larger capacity fueled by its growing pipeline of developmental and commercial manufacturing projects.
“Without this site we would never be considered for large scale commercial manufacturing,” said Michael W. Major, president and CEO of Cambridge Major Laboratories. “By default, those processes that our chemists developed and produced at smaller scale would be lost to other western competitors or offshore suppliers as the need for large scale manufacturing arises. This new facility eliminates those concerns.”
The company broke ground on the facility in June of 2008. Cambridge Major executives believe that the U.S. and Europe have become too reliant on low-cost regions of the world for supply of vital medicines.
“We have an enormous pipeline of promising early and mid-stage drug candidates that we are developing on behalf of our customer base of over 130 emerging and large pharmaceutical companies,” said Brian Scanlan, chief business officer of Cambridge Major Laboratories. “In the past, we have had to ultimately divest these opportunities to larger manufacturers due to a lack of capacity. Now we have the horsepower to take our clients new molecules from concept to full commercialization. With all of the hype surrounding drug safety and quality from offshore suppliers, (our) model has shown that U.S.-based manufacturing is still alive and well.”